UBS Group AG - BIOXCEL THERAPEUTICS INC ownership

BIOXCEL THERAPEUTICS INC's ticker is BTAI and the CUSIP is 09075P105. A total of 37 filers reported holding BIOXCEL THERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
UBS Group AG ownership history of BIOXCEL THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$198,868
-73.1%
78,604
-29.1%
0.00%
Q2 2023$738,834
-75.3%
110,936
-30.8%
0.00%
-100.0%
Q1 2023$2,990,993
+0.0%
160,289
+15.1%
0.00%0.0%
Q4 2022$2,990,317
+76.4%
139,214
-2.9%
0.00%0.0%
Q3 2022$1,695,000
+9.8%
143,388
+22.5%
0.00%0.0%
Q2 2022$1,544,000
-59.1%
117,020
-35.2%
0.00%0.0%
Q1 2022$3,776,000
-7.1%
180,564
-9.7%
0.00%0.0%
Q4 2021$4,064,000
-37.9%
199,933
-7.3%
0.00%
-50.0%
Q3 2021$6,548,000
+40.3%
215,725
+34.3%
0.00%0.0%
Q2 2021$4,667,000
-45.2%
160,603
-18.6%
0.00%
-33.3%
Q1 2021$8,519,000
+100.5%
197,369
+114.7%
0.00%
+200.0%
Q4 2020$4,248,000
+11.5%
91,949
+4.6%
0.00%0.0%
Q3 2020$3,811,000
-11.1%
87,903
+8.7%
0.00%
-50.0%
Q2 2020$4,287,000
+121.7%
80,874
-6.5%
0.00%
+100.0%
Q1 2020$1,934,000
+42.2%
86,535
-7.0%
0.00%
Q4 2019$1,360,000
+141.6%
93,084
+16.5%
0.00%
Q3 2019$563,000
-32.0%
79,902
+5.7%
0.00%
Q2 2019$828,000
+11.4%
75,562
+0.6%
0.00%
Q1 2019$743,000
+1416.3%
75,087
+490.3%
0.00%
Q4 2018$49,000
+63.3%
12,721
+225.7%
0.00%
Q3 2018$30,000
+3.4%
3,906
+22.2%
0.00%
Q2 2018$29,000
+7.4%
3,196
+20.1%
0.00%
Q1 2018$27,0002,6620.00%
Other shareholders
BIOXCEL THERAPEUTICS INC shareholders Q2 2019
NameSharesValueWeighting ↓
Knoll Capital Management, LLC 60,000$151,8000.16%
XTX Topco Ltd 33,605$85,0210.02%
Beacon Pointe Advisors, LLC 301,735$763,3900.01%
AllSquare Wealth Management LLC 4,527$11,4530.01%
Virtus ETF Advisers LLC 4,646$11,7540.01%
Y-Intercept (Hong Kong) Ltd 27,553$69,7090.01%
SeaCrest Wealth Management, LLC 16,550$41,8720.01%
Hennion & Walsh Asset Management, Inc. 33,940$85,8680.01%
Cutler Group LLC / CA 4,000$500.01%
Capital Investment Advisory Services, LLC 17,991$45,5170.00%
View complete list of BIOXCEL THERAPEUTICS INC shareholders